Prometheus Biosciences, Inc. RXDX NASDAQ

Prometheus Biosciences, Inc. (RXDX) has shown exceptional revenue growth over the past 3 years, expanding from $1M to $7M (average +94%/yr). The company reported a net loss of $142M in its most recent fiscal year, with earnings trending at -71.8%/yr. The net profit margin is -2081.8%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 100% (high), with a +0pp trend over the period. With a $10B market cap and MOAT composite score of 58/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (58/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 7-year history, the company was profitable in 0 of 7 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (58/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 36/100 with 1/7 criteria passed.